查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2006255

癌症基因治療市場：依載體類型、治療方法、適應症、疾病階段和最終用戶分類－2026-2032年全球市場預測

Cancer Gene Therapy Market by Vector Type, Therapy Type, Indication, Stage, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，癌症基因治療市場價值將達到 33 億美元，到 2026 年將成長至 39.7 億美元，到 2032 年將達到 118.1 億美元，複合年成長率為 19.96%。

主要市場統計數據
基準年 2025 33億美元
預計年份：2026年 39.7億美元
預測年份 2032 118.1億美元
複合年成長率 (%) 19.96%

我們將透過整合科學進步、遞送技術創新和切實可行的轉化策略，加速臨床上可行的癌症基因療法的出現。

癌症基因療法正處於一個轉折點，數十年的基礎科學成果正與實際臨床應用和工業化生產相融合。載體工程、遞送方法和分子標靶的最新進展已將許多概念從實驗室原理驗證試驗推進到人體試驗，並在某些情況下最終應用於臨床。同時，基因組分析、患者分層和伴隨診斷技術的進步使得治療藥物能夠更精準地匹配生物學特徵明確的患者群體，從而提高臨床療效，並為優先研發提供寶貴資訊。

新的技術突破、監管變革和不斷發展的經營模式正在重塑治療方法的設計、生產和患者獲取方式。

近年來，癌症基因治療領域發生了變革性的變化，這主要源於技術、監管和商業動態的融合，從根本上改變了專案風險評估和上市時間預測。在技​​術層面，載體設計的改進，包括最佳化趨向性和降低免疫抗原性，以及脂質體等非病毒遞送平台的創新，正在拓展其適用範圍和患者群體。同時，生產技術的進步使得更可靠的規模化生產成為可能，從而生產出產量更高、分析控制更穩定的高品質載體。這降低了批次間的差異，並支持多中心臨床開發。

評估美國關稅政策變化對原料採購、供應鏈韌性和跨境臨床營運的營運和策略影響。

影響跨境貿易的政策介入措施，例如關稅調整及相關海關措施，正開始對生技藥品和先進治療材料的採購、供應商選擇和供應鏈發展產生影響。關稅結構的變化可能會增加進口原料的成本，包括特殊脂質、質體DNA生產試劑、病毒載體原料和一次性生產組件。這些增加的投入成本可能導致早期研發公司和契約製造組織（CMO）的營運預算增加，進而可能影響供應商整合、近岸採購或垂直整合等決策。

對臨床和商業性細分進行詳細分析，揭示了載體選擇、治療方法、適應症複雜性、開發階段和最終用戶如何塑造策略重點。

一個精細的細分框架闡明了載體類型、治療方法、適應症、研發階段和最終用戶等因素如何交匯於臨床潛力和商業性可行性。按載體類型分析表明，非病毒載體和病毒載體之間的差異決定了研發重點。非病毒載體包括脂質奈米顆粒、物理方法和聚合物奈米顆粒，其優點在於生產規模化和降低長期免疫抗原性風險。另一方面，病毒載體包括腺結合病毒、腺病毒、慢病毒和逆轉錄病毒平台，其優勢在於能夠實現持續的基因改造表達和細胞特異性遞送，但需要專門的生產過程和安全性監測。此外，治療方法類型區分了體外（ex vivo）和體內（in vivo）方法。體外方法利用自體或異體細胞操作流程，而體內策略則強調直接全身或局部給予組織。

美洲、歐洲、中東和非洲以及亞太地區的區域競爭格局和病患准入趨勢正在塑造差異化的開發和商業化策略。

區域趨勢至關重要，因為法律規範、報銷環境、生產能力和患者准入模式在不同地區差異顯著。在美洲，成熟的監管管道、完善的商業性報銷機制和集中的生產生態系統支持加速臨床開發和商業化，但市場准入需要強力的衛生經濟學證據和支付方的積極參與。另一方面，歐洲、中東和非洲地區則呈現異質性。儘管歐盟內部存在協調一致的監管機制，但在報銷時間表和衛生技術評估 (HTA) 的預期方面仍存在差異。此外，中東和非洲的一些市場為建立策略夥伴關係關係以擴大市場准入提供了機會，但同時也需要製定個人化的監管和分銷策略。

整合平台差異化、生產規模和合作夥伴關係模式的企業策略，決定了哪些公司能夠從臨床潛力走向商業性成功。

一家癌症基因治療公司的發展軌跡取決於三個相互依存的因素：其科學平台的深度、生產和規模化能力，以及其在夥伴關係和許可方面的策略方針。擁有專有載體工程和遞送平台的公司可以獲得差異化的臨床優勢，但要將這種優勢轉化為臨床驗證，需要透過穩健的臨床前模型和最佳化的CMC（化學、生產和品管）流程來謹慎地降低風險。同時，透過自有投資或長期契約製造夥伴關係獲得可靠生產能力的公司可以降低執行風險，並確保按計劃完成III期臨床試驗和商業化。因此，製造地的規模和品管方面的專業知識往往是決定性的差異化因素。

生物製藥產業領導者可採取切實可行的策略步驟，以降低技術風險、加強供應鏈，並與監管機構和支付者協調，從而加快產品上市速度。

產業領導企業應採取多管齊下的行動計劃，同時應對技術風險、供應鏈脆弱性、監管複雜性以及與支付方的合作。首先，他們應優先考慮儘早選擇載體和遞送途徑，並制定明確的決策標準來評估其可轉化性、可生產性和免疫抗原性。這將減少下游流程中的失敗，並使資金集中用於最可行的方案。其次，他們應投資於靈活的生產策略，包括與獲得認證的契約製造夥伴關係、盡可能本地採購以及預留產能以降低關稅和物流風險。這些措施將提高營運韌性，並增強快速擴大成功專案規模的能力。

採用透明且可重複的研究途徑，結合對專家的初步訪談、對科學發現的二次整合以及定性檢驗，以支持可靠的結論。

本執行摘要的研究基礎包括與主要相關人員的對話以及對二手資料的系統性整合，以得出平衡且可重複的結論。一手資料包括與臨床研究人員、生產專家、監管顧問和商業領域領導者的結構化訪談和討論，旨在了解實際限制、臨床設計偏好和支付方的觀點。這些討論有助於解讀載體類型、給藥方法和臨床策略之間的技術權衡，並有助於檢驗觀察到的生產規模擴大和夥伴關係活動趨勢。

整合臨床、技術、監管和商業性因素，為不斷發展的癌症基因治療生態系統中的相關人員提供指導。

總而言之，癌症基因治療正從以探索為主的領域轉向以轉化準確性、生產準備度和商業性遠見為關鍵因素的綜合領域。載體和遞送方法的創新正在擴大治療範圍，而臨床和監管方面的洞察則不斷完善專案設計和患者選擇。同時，供應鏈的考量和政策的變化正在影響營運決策，迫使企業將採購、生產和物流與策略發展計畫相協調。因此，研發、生產、監管和商業團隊之間的跨職能整合對於降低研發管線風險和加速病患獲得治療至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按載體類型分類的癌症基因治療市場

  • 非病毒載體
    • 脂質奈米顆粒
    • 物理方法
    • 聚合物奈米粒子
  • 病毒載體
    • 腺結合病毒
    • 腺病毒
    • 慢病毒
    • 逆轉錄病毒

第9章 癌症基因治療市場（依治療方法分類）

  • Ex Vivo
  • In vivo

第10章 癌症基因治療市場：依適應症分類

  • 血癌
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
  • 固體癌
    • 乳癌
    • 結腸癌
    • 肺癌
    • 攝護腺癌

第11章 癌症基因治療市場：依階段分類

  • 臨床試驗
    • 第一階段
    • 第二階段
    • 第三階段
  • 商業的
  • 臨床前

第12章 癌症基因治療市場：依最終用戶分類

  • 醫院和診所
  • 腫瘤中心
  • 研究機構

第13章 癌症基因治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 癌症基因治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 癌症基因治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國癌症基因治療市場

第17章：中國癌症基因治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amgen Inc.
  • Autolus Therapeutics plc
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • BioNTech SE
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Candel Therapeutics, Inc.
  • CARsgen Therapeutics Holdings Limited
  • Cellectis SA
  • CRISPR Therapeutics AG
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics, Inc.
  • Iovance Biotherapeutics, Inc.
  • Janssen Biotech, Inc.
  • Kite Pharma, Inc.
  • Novartis AG
  • Precigen, Inc.
  • Sarepta Therapeutics, Inc.
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-B1685377A6FA

The Cancer Gene Therapy Market was valued at USD 3.30 billion in 2025 and is projected to grow to USD 3.97 billion in 2026, with a CAGR of 19.96%, reaching USD 11.81 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.30 billion
Estimated Year [2026] USD 3.97 billion
Forecast Year [2032] USD 11.81 billion
CAGR (%) 19.96%

Catalyzing the emergence of clinically viable cancer gene therapies through integrated scientific advances, delivery innovations, and pragmatic translational strategies

Cancer gene therapy sits at an inflection point where decades of foundational science are converging with pragmatic clinical execution and industrial-scale manufacturing. Over recent years, advances in vector engineering, delivery modalities, and molecular targeting have transitioned many concepts from laboratory proof-of-principle to human testing, and in selected cases to clinical adoption. Simultaneously, improvements in genomic profiling, patient stratification, and companion diagnostics are enabling more precise matching of therapeutic constructs to biologically defined populations, thereby improving the probability of clinical benefit and informing development prioritization.

Consequently, stakeholders across research, development, manufacturing, and commercialization must approach gene therapy with a dual lens: one that appreciates the unique scientific demands of nucleic acid delivery and one that anticipates regulatory, reimbursement, and operational realities. As a result, strategic planning today requires integrated thinking about vector selection, manufacturing capacity, clinical trial design, and payer engagement. By aligning translational science with practical implementation pathways, organizations can shorten the path from target validation to patient access while managing technical risk and capital deployment.

Emerging technological breakthroughs, regulatory recalibrations, and evolving commercial models are reshaping therapeutic design, manufacturing, and patient access pathways

Recent transformative shifts in the cancer gene therapy landscape are driven by intersecting technological, regulatory, and commercial dynamics that materially alter program risk profiles and go-to-market calculus. On the technology front, improvements in vector design, including optimized tropism and reduced immunogenicity, as well as innovations in nonviral delivery platforms such as lipid nanoparticles, have expanded the range of feasible indications and patient populations. At the same time, manufacturing technologies are scaling more reliably, enabling higher-quality vectors at improved yields and with more consistent analytical control, which reduces batch variability and supports multi-site clinical development.

From a regulatory and policy perspective, agencies are refining guidance to better address the unique safety and quality considerations of gene therapies, while payers and health technology assessment bodies are experimenting with value-based contracting and outcomes-linked reimbursement. Collectively, these shifts are lowering certain barriers to entry and increasing the strategic value of partnerships between small innovators and established manufacturers. Consequently, organizations that can combine deep translational expertise with robust manufacturing partnerships and proactive payer engagement will be best positioned to convert scientific promise into sustainable clinical impact.

Assessing the operational and strategic implications of United States tariff policy changes on raw material sourcing, supply chain resilience, and cross-border clinical operations

Policy interventions affecting cross-border trade, including tariff revisions and related customs measures, have begun to influence procurement, sourcing, and supply chain architecture for biologics and advanced therapy materials. Changes in tariff structures can increase the cost of imported raw materials such as specialty lipids, plasmid DNA production reagents, viral vector inputs, and single-use manufacturing components. These incremental input costs translate into higher operational budgets for both early-stage developers and contract manufacturing organizations, which in turn may affect decisions about supplier consolidation, near-sourcing, or vertical integration.

Moreover, tariffs exert secondary effects on logistics and inventory strategies. To mitigate exposure to unpredictable policy shifts, companies are increasingly evaluating dual-sourcing strategies, regionalized inventories, and investments in local manufacturing capability. Consequently, clinical programs with geographically distributed trial sites must balance the desire for global patient enrollment against the complexity and cost of cross-border product shipments and import/export compliance. Over time, these structural responses can reshape partnership models and influence where organizations choose to site critical manufacturing and fill-finish operations, thereby altering the economics and speed of clinical and commercial deployment.

Disaggregated clinical and commercial segmentation reveals how vector choice, therapeutic modality, indication complexity, development stage, and end users shape strategic priorities

A nuanced segmentation framework clarifies where clinical promise intersects with commercial practicality across vector modalities, therapeutic approaches, indications, development stages, and end users. When analyzed by vector type, distinctions between nonviral and viral vectors shape R&D priorities: nonviral vectors encompass lipid nanoparticles, physical methods, and polymeric nanoparticles, offering advantages in manufacturing scalability and reduced long-term immunogenicity concerns, while viral vectors include adeno-associated, adenoviral, lentiviral, and retroviral platforms that provide durable transgene expression and cell-specific delivery advantages but demand specialized manufacturing and safety monitoring. Complementing this, therapy type differentiates ex vivo and in vivo approaches, with ex vivo modalities leveraging autologous or allogeneic cell manipulation workflows and in vivo strategies emphasizing direct systemic or localized delivery to tissues.

Indication segmentation further refines clinical strategy. Hematological cancers, including leukemia, lymphoma, and myeloma, have been fertile ground for adoptive cell therapies and targeted gene modifications because of accessible cell sources and well-characterized biomarkers, whereas solid tumors such as breast cancer, colorectal cancer, lung cancer, and prostate cancer present delivery barriers and immunosuppressive microenvironments that necessitate novel targeting and combination approaches. Stage segmentation is equally consequential: preclinical work informs vector selection and nonclinical safety profiling, clinical trials span Phase I, Phase II, and Phase III with escalating complexity in endpoint selection and operational scale, and commercial programs require robust quality systems and distribution networks. Finally, end users such as hospitals and clinics, specialized oncology centers, and research laboratories impose distinct demands on product presentation, cold chain logistics, training requirements, and reimbursement interactions. Taken together, these interlocking segmentation dimensions determine technology risk, capital intensity, partner selection, and commercialization pathways.

Regional competitive contours and patient access narratives across the Americas, Europe Middle East & Africa, and Asia-Pacific shape differentiated development and commercialization strategies

Regional dynamics matter because regulatory frameworks, reimbursement environments, manufacturing capacity, and patient access models differ substantially across geographies. In the Americas, mature regulatory pathways, established commercial reimbursement mechanisms, and concentrated manufacturing ecosystems support accelerated clinical development and commercialization, but market access requires robust health economic evidence and payer engagement. Conversely, Europe, Middle East & Africa exhibit heterogeneity: EU jurisdictions offer coordinated regulatory mechanisms yet diverge on reimbursement timelines and HTA expectations, while certain markets in the Middle East and Africa present opportunities for strategic partnerships to expand access but necessitate tailored regulatory and distribution strategies.

In the Asia-Pacific region, rapid investments in local manufacturing, rising clinical trial activity, and growing government support for biotechnology create fertile conditions for clinical translation and regional supply chains. However, differences in regulatory harmonization, patient population genetics, and healthcare infrastructure mean that go-to-market plans must be regionally adapted. Therefore, organizations should prioritize regulatory intelligence, localized clinical pathways, and supply chain resiliency when establishing presence across the Americas, Europe, Middle East & Africa, and Asia-Pacific to ensure that development timelines and commercial rollouts remain aligned with regional realities.

Company strategies that integrate platform differentiation, manufacturing scale, and collaborative partnership models determine who advances from clinical promise to commercial impact

Company-level trajectories in cancer gene therapy are driven by three interdependent factors: the depth of scientific platform, manufacturing and scale capabilities, and the strategic posture toward partnerships and licensing. Organizations with proprietary vector engineering or delivery platforms can capture differentiated clinical advantages, but translating those advantages into clinical proof requires careful de-risking through robust preclinical models and optimized CMC pathways. In parallel, companies that secure reliable manufacturing capacity-either through in-house investment or long-term contract manufacturing partnerships-reduce execution risk and maintain timelines for pivotal studies and commercial launches. Thus, manufacturing footprint and quality control expertise often become decisive differentiators.

Furthermore, firms adopting collaborative business models that combine early-stage innovation with established commercial or manufacturing partners tend to accelerate patient access while preserving upside through milestone and royalty structures. Strategic alliances that align clinical development plans, regulatory submission strategies, and market access evidence generation help firms navigate HTA negotiations and payer dialogues. Ultimately, the most successful companies will be those that integrate scientific differentiation with pragmatic manufacturing strategies and thoughtful commercial partnerships to move therapies from proof-of-concept to reliable patient delivery.

Actionable strategic measures for biopharma leaders to reduce technical risk, reinforce supply chains, and align regulatory and payer engagement for accelerated access

Industry leaders should adopt a multi-pronged action plan that addresses technical risk, supply chain fragility, regulatory complexity, and payer engagement concurrently. First, prioritize vector and delivery selection early with clear decision gates that weigh translatability, manufacturability, and immunogenicity; this reduces downstream attrition and focuses capital on the most viable constructs. Second, invest in flexible manufacturing strategies that include qualified contract manufacturing partnerships, near-sourcing where feasible, and contingency capacity to mitigate tariff and logistics risks. These moves improve operational resilience and accelerate the ability to scale successful programs.

Third, engage regulators and payers proactively to align on evidentiary needs, safety monitoring frameworks, and value demonstration pathways; early alignment reduces the risk of late-stage surprises and facilitates smoother reimbursement discussions. Fourth, design clinical programs that incorporate robust biomarker strategies and adaptive elements to enhance patient selection and endpoint sensitivity. Finally, pursue partnerships that augment internal capabilities-whether for manufacturing, regulatory expertise, or commercial infrastructure-so that scientific innovators can leverage complementary strengths and accelerate patient access. Taken together, these actions create a pragmatic roadmap for converting scientific innovation into durable clinical and commercial outcomes.

A transparent and reproducible research approach combining primary expert interviews, secondary scientific synthesis, and qualitative validation to support robust conclusions

The research underpinning this executive summary integrated primary stakeholder engagement with systematic secondary synthesis to ensure balanced, reproducible conclusions. Primary inputs included structured interviews and consultations with clinical investigators, manufacturing experts, regulatory advisors, and commercial leaders to capture real-world operational constraints, clinical design preferences, and payer perspectives. These discussions informed the interpretation of technical tradeoffs between vector types, delivery methods, and clinical strategies, and helped validate observed trends in manufacturing scale-up and partnership activity.

Secondary research involved a comprehensive review of peer-reviewed literature, regulatory guidance documents, conference proceedings, and company disclosures to map technological developments and regulatory evolution. Throughout the process, qualitative validation steps such as cross-checking assertions with multiple independent experts and reconciling divergent viewpoints were applied to reduce bias. Finally, findings were synthesized to highlight strategic implications rather than to produce proprietary market metrics, ensuring the analysis emphasizes actionable intelligence for decision-makers while remaining transparent about methodology and evidence sources.

Synthesis of clinical, technical, regulatory, and commercial considerations to guide stakeholders through the evolving gene therapy oncology ecosystem

In summary, cancer gene therapy is transitioning from a predominantly exploratory field to one in which translational fidelity, manufacturing readiness, and commercial foresight jointly determine success. Vector and delivery innovations broaden the therapeutic scope, while clinical and regulatory learnings refine program design and patient selection. Meanwhile, supply chain considerations and policy shifts influence operational choices, compelling organizations to align sourcing, manufacturing, and logistics with strategic development plans. As a result, cross-functional integration across R&D, manufacturing, regulatory, and commercial teams is essential to de-risk pipelines and accelerate patient access.

Looking ahead, the ecosystem will reward entities that combine rigorous translational science with disciplined program management and strategic partnerships. By focusing on modular manufacturing investments, proactive regulatory engagement, and evidence generation that resonates with payers, developers can improve the predictability of development pathways and enhance the likelihood of sustainable clinical impact. Ultimately, careful orchestration of technical, operational, and commercial activities will determine which therapies achieve broad patient adoption and which programs stall despite promising biology.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Gene Therapy Market, by Vector Type

  • 8.1. Nonviral Vectors
    • 8.1.1. Lipid Nanoparticles
    • 8.1.2. Physical Methods
    • 8.1.3. Polymeric Nanoparticles
  • 8.2. Viral Vectors
    • 8.2.1. Adeno-Associated
    • 8.2.2. Adenoviral
    • 8.2.3. Lentiviral
    • 8.2.4. Retroviral

9. Cancer Gene Therapy Market, by Therapy Type

  • 9.1. Ex Vivo
  • 9.2. In Vivo

10. Cancer Gene Therapy Market, by Indication

  • 10.1. Hematological Cancers
    • 10.1.1. Leukemia
    • 10.1.2. Lymphoma
    • 10.1.3. Myeloma
  • 10.2. Solid Tumors
    • 10.2.1. Breast Cancer
    • 10.2.2. Colorectal Cancer
    • 10.2.3. Lung Cancer
    • 10.2.4. Prostate Cancer

11. Cancer Gene Therapy Market, by Stage

  • 11.1. Clinical Trials
    • 11.1.1. Phase I
    • 11.1.2. Phase II
    • 11.1.3. Phase III
  • 11.2. Commercial
  • 11.3. Preclinical

12. Cancer Gene Therapy Market, by End User

  • 12.1. Hospitals And Clinics
  • 12.2. Oncology Centers
  • 12.3. Research Laboratories

13. Cancer Gene Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cancer Gene Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cancer Gene Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cancer Gene Therapy Market

17. China Cancer Gene Therapy Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Amgen Inc.
  • 18.6. Autolus Therapeutics plc
  • 18.7. Bayer AG
  • 18.8. BioMarin Pharmaceutical Inc.
  • 18.9. BioNTech SE
  • 18.10. bluebird bio, Inc.
  • 18.11. Bristol-Myers Squibb Company
  • 18.12. Candel Therapeutics, Inc.
  • 18.13. CARsgen Therapeutics Holdings Limited
  • 18.14. Cellectis S.A.
  • 18.15. CRISPR Therapeutics AG
  • 18.16. F. Hoffmann-La Roche Ltd
  • 18.17. Fate Therapeutics, Inc.
  • 18.18. Iovance Biotherapeutics, Inc.
  • 18.19. Janssen Biotech, Inc.
  • 18.20. Kite Pharma, Inc.
  • 18.21. Novartis AG
  • 18.22. Precigen, Inc.
  • 18.23. Sarepta Therapeutics, Inc.
  • 18.24. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHYSICAL METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHYSICAL METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHYSICAL METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENOVIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENOVIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENOVIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LENTIVIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LENTIVIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LENTIVIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RETROVIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RETROVIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RETROVIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY EX VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY IN VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. GCC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. GCC CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 203. GCC CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 204. GCC CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. GCC CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. GCC CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 207. GCC CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 208. GCC CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 209. GCC CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. G7 CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. G7 CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. G7 CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 236. G7 CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 237. G7 CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. G7 CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 239. G7 CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 240. G7 CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 241. G7 CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 242. G7 CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 243. G7 CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. NATO CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. NATO CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. NATO CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 247. NATO CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 248. NATO CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. NATO CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 250. NATO CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 251. NATO CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 252. NATO CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 253. NATO CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 254. NATO CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)